{"filing":{"accession_number":"0001104659-26-088728","cik":"0001137883","ticker":"BCLI","company_name":"BRAINSTORM CELL THERAPEUTICS INC.","form":"8-K","filing_date":"2026-07-30","report_date":"2026-07-24","primary_document":"tm2621592d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465926088728/tm2621592d1_8k.htm"},"events":[{"id":22230,"run_id":20099,"accession_number":"0001104659-26-088728","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"Peter Pitts was appointed as Executive Chairman and Chief Strategic Regulatory Officer effective July 24, 2026, with a 900,000-share stock option grant. The appointment represents a significant leadership transition, with Pitts, a former FDA Associate Commissioner, assuming operational control over daily strategic operations and clinical-regulatory pathways for the company's Phase 3b trial. Jacob Frenkel resigned as Chairman and transitioned to Senior Advisor, and Ibrahim Dagher departed as Chief Medical Officer.","company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","filing_date":"2026-07-30","form":"8-K","submitted_at":null,"items":[{"id":22110,"accession_number":"0001104659-26-088728","item_number":"5.02","item_title":"Departure of Directors or Principal Officers; Election","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses the appointment of Peter Pitts as Executive Chairman and Chief Strategic Regulatory Officer on July 24, 2026, with a 900,000-share stock option grant. While the section also includes the resignation of Jacob Frenkel as Chairman and Ibrahim Dagher as Chief Medical Officer, the primary focus and lead disclosure is Pitts's appointment to an active executive leadership role overseeing daily strategic operations and clinical-regulatory pathways for the company's Phase 3b trial. This is material to investors as it represents a significant leadership transition with a former FDA Associate Commissioner assuming operational control.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-31T00:18:07.029756+00:00","company_name":"","ticker":null,"filing_date":""},{"id":22111,"accession_number":"0001104659-26-088728","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses the appointment of Peter J. Pitts as Executive Chairman and Chief Strategic Regulatory and Policy Officer, with immediate leadership over daily strategic operations and clinical-regulatory pathways. While Professor Jacob Frenkel's transition to Senior Advisor is also mentioned, the principal disclosed action centers on Pitts's appointment to an active executive leadership role. The appointment of a former FDA Associate Commissioner to lead a biotech company's Phase 3b trial execution is material to investors assessing the registrant's regulatory and operational capabilities.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-31T00:18:07.029756+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22110,"accession_number":"0001104659-26-088728","item_number":"5.02","item_title":"Departure of Directors or Principal Officers; Election","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses the appointment of Peter Pitts as Executive Chairman and Chief Strategic Regulatory Officer on July 24, 2026, with a 900,000-share stock option grant. While the section also includes the resignation of Jacob Frenkel as Chairman and Ibrahim Dagher as Chief Medical Officer, the primary focus and lead disclosure is Pitts's appointment to an active executive leadership role overseeing daily strategic operations and clinical-regulatory pathways for the company's Phase 3b trial. This is material to investors as it represents a significant leadership transition with a former FDA Associate Commissioner assuming operational control.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-31T00:18:07.029756+00:00","company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","filing_date":"2026-07-30"},{"id":22111,"accession_number":"0001104659-26-088728","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses the appointment of Peter J. Pitts as Executive Chairman and Chief Strategic Regulatory and Policy Officer, with immediate leadership over daily strategic operations and clinical-regulatory pathways. While Professor Jacob Frenkel's transition to Senior Advisor is also mentioned, the principal disclosed action centers on Pitts's appointment to an active executive leadership role. The appointment of a former FDA Associate Commissioner to lead a biotech company's Phase 3b trial execution is material to investors assessing the registrant's regulatory and operational capabilities.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-31T00:18:07.029756+00:00","company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","filing_date":"2026-07-30"}]}